Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment

Autor: Yan Felix Karl Dyck, Daniel Rehm, Jan Felix Joseph, Karsten Winkler, Volker Sandig, Wolfgang Jabs, Maria Kristina Parr
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Bioengineering, Vol 6, Iss 3, p 62 (2019)
Druh dokumentu: article
ISSN: 2306-5354
DOI: 10.3390/bioengineering6030062
Popis: Oxidation of monoclonal antibodies (mAbs) can impact their efficacy and may therefore represent critical quality attributes (CQA) that require evaluation. To complement classical CQA, bevacizumab and infliximab were subjected to oxidative stress by H2O2 for 24, 48, or 72 h to probe their oxidation susceptibility. For investigation, a middle-up approach was used utilizing liquid chromatography hyphenated with mass spectrometry (LC-QTOF-MS). In both mAbs, the Fc/2 subunit was completely oxidized. Additional oxidations were found in the light chain (LC) and in the Fd’ subunit of infliximab, but not in bevacizumab. By direct comparison of methionine positions, the oxidized residues in infliximab were assigned to M55 in LC and M18 in Fd’. The forced oxidation approach was further exploited for comparison of respective biosimilar products. Both for bevacizumab and infliximab, comparison of posttranslational modification profiles demonstrated high similarity of the unstressed reference product (RP) and the biosimilar (BS). However, for bevacizumab, comparison after forced oxidation revealed a higher susceptibility of the BS compared to the RP. It may thus be considered a useful tool for biopharmaceutical engineering, biosimilarity assessment, as well as for quality control of protein drugs.
Databáze: Directory of Open Access Journals